PDCD1 and neoplasm: When combined with immune checkpoint blockade therapy (anti-PD-1, anti-PD-L1, and anti-CTLA-4), significant tumor remission was observed, indicating that anti-tumor immunity induced by L. monocytogenes vaccination could be further enhanced with immune checkpoint blockade therapy (116).